These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

774 related articles for article (PubMed ID: 32726528)

  • 21. Monoclonal Antibody for the Prevention of Respiratory Syncytial Virus in Infants and Children: A Systematic Review and Network Meta-analysis.
    Sun M; Lai H; Na F; Li S; Qiu X; Tian J; Zhang Z; Ge L
    JAMA Netw Open; 2023 Feb; 6(2):e230023. PubMed ID: 36800182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population Pharmacokinetics of Nirsevimab in Preterm and Term Infants.
    Clegg L; Freshwater E; Leach A; Villafana T; Hamrén UW
    J Clin Pharmacol; 2024 May; 64(5):555-567. PubMed ID: 38294353
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants.
    Blanken MO; Rovers MM; Molenaar JM; Winkler-Seinstra PL; Meijer A; Kimpen JL; Bont L;
    N Engl J Med; 2013 May; 368(19):1791-9. PubMed ID: 23656644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
    Fleming-Dutra KE; Jones JM; Roper LE; Prill MM; Ortega-Sanchez IR; Moulia DL; Wallace M; Godfrey M; Broder KR; Tepper NK; Brooks O; Sánchez PJ; Kotton CN; Mahon BE; Long SS; McMorrow ML
    MMWR Morb Mortal Wkly Rep; 2023 Oct; 72(41):1115-1122. PubMed ID: 37824423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nirsevimab and Hospitalization for RSV Bronchiolitis.
    Assad Z; Romain AS; Aupiais C; Shum M; Schrimpf C; Lorrot M; Corvol H; Prevost B; Ferrandiz C; Giolito A; Valtuille Z; Bendavid M; Cohen JF; Toubiana J; de Pontual L; Delande CF; Levy M; See P; Cohen R; Levy C; Angoulvant F; Lenglart L; Gits-Muselli M; Biran V; Diallo K; Alemede O; El Hebil MM; Durrmeyer X; Labouret G; Casanovas N; Hallak B; Maréchal O; Jung C; Bréhin C; Ouldali N
    N Engl J Med; 2024 Jul; 391(2):144-154. PubMed ID: 38986058
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of palivizumab prophylaxis on the frequency of RSV-associated lower respiratory tract infections in preterm infants: determination of the ideal target population for prophylaxis.
    Cetinkaya M; Oral TK; Karatekin S; Cebeci B; Babayigit A; Yesil Y
    Eur J Clin Microbiol Infect Dis; 2017 Sep; 36(9):1629-1634. PubMed ID: 28391538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of antibody-based preventive alternatives for respiratory syncytial virus: a novel multi-criteria decision analysis framework and assessment of nirsevimab in Spain.
    Mestre-Ferrándiz J; Rivero A; Orrico-Sánchez A; Hidalgo Á; Abdalla F; Martín I; Álvarez J; García-Cenoz M; Del Carmen Pacheco M; Garcés-Sánchez M; Zozaya N; Ortiz-de-Lejarazu R
    BMC Infect Dis; 2024 Jan; 24(1):99. PubMed ID: 38238680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early estimates of nirsevimab immunoprophylaxis effectiveness against hospital admission for respiratory syncytial virus lower respiratory tract infections in infants, Spain, October 2023 to January 2024.
    López-Lacort M; Muñoz-Quiles C; Mira-Iglesias A; López-Labrador FX; Mengual-Chuliá B; Fernández-García C; Carballido-Fernández M; Pineda-Caplliure A; Mollar-Maseres J; Shalabi Benavent M; Sanz-Herrero F; Zornoza-Moreno M; Pérez-Martín JJ; Alfayate-Miguelez S; Pérez Crespo R; Bastida Sánchez E; Menasalvas-Ruiz AI; Téllez-González MC; Esquiva Soto S; Del Toro Saravia C; Sanz-Muñoz I; Eiros JM; Matías Del Pozo V; Toquero-Asensi M; Pastor-Villalba E; Lluch-Rodrigo JA; Díez-Domingo J; Orrico-Sánchez A
    Euro Surveill; 2024 Feb; 29(6):. PubMed ID: 38333937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants.
    Pedraz C; Carbonell-Estrany X; Figueras-Aloy J; Quero J;
    Pediatr Infect Dis J; 2003 Sep; 22(9):823-7. PubMed ID: 14506376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
    Jones JM; Fleming-Dutra KE; Prill MM; Roper LE; Brooks O; Sánchez PJ; Kotton CN; Mahon BE; Meyer S; Long SS; McMorrow ML
    MMWR Morb Mortal Wkly Rep; 2023 Aug; 72(34):920-925. PubMed ID: 37616235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Infant respiratory syncytial virus prophylaxis and nasopharyngeal microbiota until 6 years of life: a subanalysis of the MAKI randomised controlled trial.
    Man WH; Scheltema NM; Clerc M; van Houten MA; Nibbelke EE; Achten NB; Arp K; Sanders EAM; Bont LJ; Bogaert D
    Lancet Respir Med; 2020 Oct; 8(10):1022-1031. PubMed ID: 32203712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants.
    Simões EAF; Forleo-Neto E; Geba GP; Kamal M; Yang F; Cicirello H; Houghton MR; Rideman R; Zhao Q; Benvin SL; Hawes A; Fuller ED; Wloga E; Pizarro JMN; Munoz FM; Rush SA; McLellan JS; Lipsich L; Stahl N; Yancopoulos GD; Weinreich DM; Kyratsous CA; Sivapalasingam S
    Clin Infect Dis; 2021 Dec; 73(11):e4400-e4408. PubMed ID: 32897368
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of nirsevimab immunoprophylaxis against respiratory syncytial virus-related outcomes in hospital and primary care settings: a retrospective cohort study in infants in Catalonia (Spain).
    Coma E; Martinez-Marcos M; Hermosilla E; Mendioroz J; Reñé A; Fina F; Perramon-Malavez A; Prats C; Cereza G; Ciruela P; Pineda V; Antón A; Ricós-Furió G; Soriano-Arandes A; Cabezas C
    Arch Dis Child; 2024 Aug; 109(9):736-741. PubMed ID: 38857952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nirsevimab: A Review.
    Balbi H
    Pediatr Allergy Immunol Pulmonol; 2024 Mar; 37(1):3-6. PubMed ID: 38484270
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal Respiratory Syncytial Virus intervention programmes using Nirsevimab in England and Wales.
    Hodgson D; Koltai M; Krauer F; Flasche S; Jit M; Atkins KE
    Vaccine; 2022 Nov; 40(49):7151-7157. PubMed ID: 36328884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials.
    Ahani B; Tuffy KM; Aksyuk AA; Wilkins D; Abram ME; Dagan R; Domachowske JB; Guest JD; Ji H; Kushnir A; Leach A; Madhi SA; Mankad VS; Simões EAF; Sparklin B; Speer SD; Stanley AM; Tabor DE; Hamrén UW; Kelly EJ; Villafana T
    Nat Commun; 2023 Jul; 14(1):4347. PubMed ID: 37468530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nirsevimab: review of pharmacology, antiviral activity and emerging clinical experience for respiratory syncytial virus infection in infants.
    Jorgensen SCJ
    J Antimicrob Chemother; 2023 May; 78(5):1143-1149. PubMed ID: 36922390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Respiratory syncytial virus].
    Tsutsumi H
    Uirusu; 2005 Jun; 55(1):77-84. PubMed ID: 16308533
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single Intramuscular Dose of Nirsevimab Reduces Likelihood of Hospitalization Due to RSV in Average-Risk Infants During First Year of Life.
    Ebell MH
    Am Fam Physician; 2024 May; 109(5):477-478. PubMed ID: 38804769
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.